Albumin-binding MR blood pool agents as MRI contrast agents in an intracranial mouse glioma model. |
| |
Authors: | Kofi Adzamli Dmitriy A Yablonskiy Michael R Chicoine Eun Kyung Won Karen P Galen Michael C Zahner Thomas A Woolsey Joseph J H Ackerman |
| |
Affiliation: | Imaging Division, Mallinckrodt, Inc., St. Louis, Missouri 63110, USA. |
| |
Abstract: | Intravenous MRI contrast agents are commonly used to improve the detection of intracranial tumors and other central nervous system (CNS) lesions for diagnosis and treatment planning. Two small-molecule, albumin-binding blood pool contrast agents (MP-2269 and MS-325) of potential clinical significance were evaluated at 1.5 Tesla in a mouse glioma model and compared with an extracellular contrast agent (OptiMARK). Tumor image contrast was significantly enhanced and long-lived following administration of 30 micromole/kg of the blood pool agents: specifically, contrast enhancement peaked slowly at 25-30 min following administration, remained constant for >3 hr, and returned to baseline within 20 hr. Comparable but "transient" enhancement was achieved using 100 micromole/kg OptiMARK: specifically, contrast enhancement peaked rapidly at 2-5 min following administration and then declined over 40 min. The blood pool contrast agents demonstrated an approximately threefold increased dose-effectiveness and a lengthened window of tumor contrast enhancement in comparison to commonly available extracellular contrast agents. This demonstrates the potential of alternative contrast-enhanced (CE) MRI examination protocols for tumor detection. |
| |
Keywords: | MR contrast media blood pool agent brain tumor mouse glioma model MRI |
|
|